(Q34805117)

4 August 2017

1 reference

title

Combined therapy of pilocarpine or latanoprost with timolol versus latanoprost monotherapy (English)

1 reference

4 August 2017

1 reference

1 reference

Michael Diestelhorst

1

1 reference

PubMed ID

12204713

4 August 2017

Jean-Philippe Nordmann

series ordinal

2

1 reference

PubMed ID

12204713

4 August 2017

Carol B Toris

series ordinal

3

1 reference

4 August 2017

1 August 2002

1 reference

4 August 2017

Survey of Ophthalmology

1 reference

4 August 2017

47 Suppl 1

1 reference

4 August 2017

S155-61

1 reference

Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States.

4 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900329-6

7 January 2021

Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900329-6

7 January 2021

Additive IOP-reducing effect of latanoprost in patients insufficiently controlled on timolol

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900329-6

7 January 2021

Effect of chronically administered timolol on aqueous humor flow in patients with glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900329-6

7 January 2021

Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900329-6

7 January 2021

Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900329-6

7 January 2021

Latanoprost treatment for glaucoma: effects of treating for 1 year and of switching from timolol. United States Latanoprost Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900329-6

7 January 2021

The mechanism of timolol in lowering intraocular pressure. In the normal eye.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900329-6

7 January 2021

The effects of timolol maleate and acetazolamide on the rate of aqueous formation in normal human subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900329-6

7 January 2021

The additive intraocular pressure-lowering effect of latanoprost 0.005% daily once and pilocarpine 2% t.i.d. in patients with open-angle glaucoma or ocular hypertension. a 6-month, randomized, multicenter study. German Latanoprost Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900329-6

7 January 2021

Comparison of the effect of latanoprost 0.005% and timolol 0.5% on the calculated ocular perfusion pressure in patients with normal-tension glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900329-6

7 January 2021

Comparison of latanoprost monotherapy to dorzolamide combined with timolol in patients with glaucoma and ocular hypertension.A 3-month randomised study

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900329-6

7 January 2021

Prostaglandin F2 alpha increases uveoscleral outflow in the cynomolgus monkey

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900329-6

7 January 2021

Reduced intraocular pressure and increased ocular perfusion pressure in normal tension glaucoma: a review of short-term studies with three dose regimens of latanoprost treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900329-6

7 January 2021

Nocturnal arterial hypotension and its role in optic nerve head and ocular ischemic disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900329-6

7 January 2021

The effect on diurnal intraocular pressure of the fixed combination of latanoprost 0.005% and timolol 0.5% in patients with ocular hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900329-6

7 January 2021

A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900329-6

7 January 2021

Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2 alpha-1-isopropylester in the cynomolgus monkey.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900329-6

7 January 2021

Comparison of the intraocular pressure lowering effect of latanoprost and a fixed combination of timolol-pilocarpine eye drops in patients insufficiently controlled with beta adrenergic antagonists. French Latanoprost Study Group, and the Swedish La

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900329-6

7 January 2021

Timolol-pilocarpine fixed-ratio combinations in the treatment of chronic open angle glaucoma. A controlled multicenter study of 48 weeks. Scandinavian Timpilo Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900329-6

7 January 2021

Around-the-clock intraocular pressure reduction with once-daily application of latanoprost by itself or in combination with timolol.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900329-6

7 January 2021

Additive effect of latanoprost, a prostaglandin F2 alpha analogue, and timolol in patients with elevated intraocular pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900329-6

7 January 2021

Fluorophotometric study of epinephrine and timolol in human subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900329-6

7 January 2021

Ocular and systemic pharmacokinetics of latanoprost in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900329-6

7 January 2021

Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900329-6

7 January 2021

A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900329-6

7 January 2021

Latanoprost. Two years' experience of its use in the United Kingdom. Latanoprost Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900329-6

7 January 2021

A fluorophotometric study of the effect of topical timolol on aqueous humor dynamics

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900329-6

7 January 2021

Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900329-6

7 January 2021

The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2802%2900329-6

7 January 2021

10.1016/S0039-6257(02)00329-6

Identifiers

DOI

1 reference

4 August 2017

1 reference

PubMed ID

12204713